Medtronic set to launch CRT-pacemaker

The FDA approved a cardiac resynchronization therapy-pacemaker (CRT-P) for patients with heart failure or atrioventricular block.

Medtronic announced that it received the OK to launch its Viva CRT-P device in the U.S. The company won approval in Europe for the same technology in May.

Viva CRT-P uses a proprietary algorithm, AdaptivCRT, which in studies has shown clinical and economic benefits. In heart failure patients, it helped to improve response to the therapy, reduce the risk of atrial fibrillation and reduce 30-day hospital readmissions and related resource use. In addition, the device includes diagnostics tools for monitoring fluid status and assessing patients’ physiological condition.